Item 2.02. Results of Operations and Financial Condition.
On August 14, 2019, Windtree Therapeutics, Inc. (the "Company") issued a press
release highlighting the results of operations for the quarter ended June 30,
2019 and providing key financial and business updates. The press release is
attached as Exhibit 99.1 hereto.
In accordance with General Instruction B.2 of Form 8-K, the information in Item
2.02 of this Current Report on Form 8-K and Exhibit 99.1 hereto relating to the
announcement of the results of operations for the quarter ended June 30, 2019
and all other matters except for those discussed under Item 8.01 below shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in any such filings.
Item 8.01. Other Events.
The press release referred to in Item 2.02 also provides certain program updates
relating to the Company's lead programs - istaroxime for acute heart failure and
AEROSURF® for respiratory distress syndrome (RDS) in premature infants. In
addition, the Company reports that, before any additional financings, the
Company anticipates that it will have sufficient cash, cash equivalents and
available-for-sale marketable securities to fund its development activities,
business operations and debt service through October 2019.
Subject to the note relating to the press release contained in Item 2.02 of this
Current Report on Form 8-K, the press release is attached as Exhibit 99.1
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release of Windtree Therapeutics, Inc., dated August 14, 2019.
Cautionary Note Regarding Forward-looking Statements:
To the extent that statements in this Current Report on Form 8-K are not
strictly historical, including statements as to business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future financial
conditions, future collaboration agreements, the success of the Company's
product development, cash flows, future revenues, the timing of planned clinical
trials or otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this
Current Report are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made. Such risks and
others are further described in the Company's filings with the Securities and
Exchange Commission including the most recent reports on Forms 10-K, 10-Q and
8-K, and any amendments thereto. Any forward-looking statement made by the
Company in this Current Report on Form 8-K is based only on information
currently available to the Company and speaks only as of the date on which it is
made. The Company undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or
© Edgar Online, source Glimpses